SolarEdge Technologies enters the final days of August caught between two sharply opposing forces: a fresh upgrade from a major bank and the heaviest short positioning in months.
The most striking development this week came from the analyst community. UBS upgraded SEDG to Buy on August 26, lifting its target from $36 to $42 — a meaningful vote of confidence from a bellwether firm, and one that runs directly against the prevailing Street mood. The rest of the analyst cohort is firmly on the sidelines: 19 Hold ratings, just 2 Buys, and a Goldman Sachs Sell that came with a $30 target set right at current prices. The consensus mean target sits at $39.15, a roughly 31% premium to the $29.88 close, but that figure is dragged upward by outliers — TD Cowen still carries a $75 target that looks badly out of step with the post-earnings reality. Goldman's Sell and the cluster of $24–$38 targets from RBC, Barclays, and Susquehanna, all cut sharply after the August 5 earnings collapse, tell a more honest story about where the Street's centre of gravity actually lies.
That earnings print is the backdrop for everything. SEDG fell 33% on August 5 alone and shed another point over the following five days, compressing the stock by roughly 30% over the past month to sit just under $30. The bear case is well-rehearsed: post-2025 residential solar demand weakness as tax incentives fade, margin pressure from rising operational costs, and electricity-price volatility undercutting the economics of solar adoption. The bull case — a booming US commercial and industrial pipeline, product scarcity in the C&I segment, and battery-market share gains — gives UBS its rationale for the upgrade, but it is a minority view right now.
Short sellers are pressing hard on the bearish side. Short interest climbed to 20.9% of the free float as of August 25, up 10% in a single session and nearly 16% higher than a month ago. That is a material build, and it is happening fast. The ORTEX short score has ticked up to 71.4 — a 10-day high — reflecting the weight of recent positioning. Despite the size of the short book, the borrow market remains surprisingly relaxed: cost to borrow runs at just 0.68%, barely changed over the month, and availability has loosened to around 53% of short interest from a tighter 29% in mid-August. Short sellers face no meaningful squeeze pressure from the lending market right now. Factor scores reinforce the picture — short score ranks in the bottom 3rd percentile of the universe, and days-to-cover ranks near the bottom 4th percentile, flagging this as one of the more heavily shorted names across the board.
Options positioning nudged slightly more defensive on August 25, with the put/call ratio rising to 0.60 — above its 20-day average of 0.56 — but only about one standard deviation from the mean. That is not an alarm reading. The 52-week high on the PCR stands at 0.95, and the current level sits comfortably in the middle of the past year's range. Peers painted a broadly weaker tape this week: ENPH slipped 0.6% and FSLR fell 6%, while ARM and ALAB dropped 4–7%, suggesting semiconductor and solar names alike faced selling pressure — making SEDG's flat weekly performance a mild relative win despite the macro drag.
Institutional ownership adds an interesting wrinkle. BlackRock added over 1.1 million shares in the July reporting period, lifting its stake to 15.6% of shares outstanding. American Century added 937,000 shares in the same window. Harel Insurance built a fresh position of 2.3 million shares. Against that, Menora trimmed by 380,000 shares and Vanguard cut by 112,000. The net picture is one of selective accumulation by some large holders even as others trim — hardly a uniform rush for the exit.
The next scheduled catalyst is the Q3 earnings print on November 4. Until then, the tension between UBS's fresh Buy conviction and the 20%-plus short interest at an elevated short score is the defining dynamic to watch.
See the live data behind this article on ORTEX.
Open SEDG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
